Bone loss in response to long-term glucocorticoid therapy

Area of Science:

• Endocrinology
• Bone Biology
• Pharmacology

Background:

• Glucocorticoids are known to induce osteoporosis, but the precise mechanisms and timeline of bone mass reduction are not fully understood.
• Long-term glucocorticoid therapy is common for various medical conditions, necessitating a clear understanding of its skeletal side effects.

Purpose of the Study:

• To elucidate the mechanisms and time course of bone mass reduction during long-term glucocorticoid treatment.
• To investigate the impact of prednisone on bone histomorphometry and biochemical markers.

Main Methods:

• A longitudinal clinical and histomorphometric study involving 23 patients (9 men, 14 women) treated with prednisone (10-25 mg/day).
• Bone biopsies of the iliac crest were analyzed for histomorphometric parameters before and during treatment.
• Biochemical markers of bone metabolism and serum calcium levels were monitored.

Main Results:

• Trabecular bone volume (TBV) decreased by up to 27% within the first 5-7 months, with minor changes thereafter, fitting a negative exponential function.
• Histological analysis revealed a lack of osteoblastic activity and reduced bone formation rates, but no significant increase in bone resorption.
• Biochemical markers showed no significant changes in alkaline phosphatase or vitamin D metabolites, but serum calcium transiently increased, and urinary hydroxyproline excretion decreased.

Conclusions:

• Long-term glucocorticoid therapy leads to reduced bone turnover and significant bone loss, predominantly in the initial 6 months of treatment.
• The primary mechanism appears to be decreased bone formation rather than increased bone resorption.
• Patients with lower baseline bone mass may experience a slower rate of bone loss during glucocorticoid therapy.